InvestorsHub Logo
Followers 13
Posts 697
Boards Moderated 0
Alias Born 01/12/2013

Re: joboggi post# 110313

Saturday, 12/13/2014 2:33:15 PM

Saturday, December 13, 2014 2:33:15 PM

Post# of 130503

I have posted the LymPro section of the November 7th 10-Q (look at the last sentence....."92% co-positivity and 91% co-negativity with an overall 95% accuracy rating for LymPro".

Please work harder to get your facts straight!!

LymPro Test ?

The Lymphocyte Proliferation Test ("LymPro Test ?", or "LymPro") is a diagnostic blood test for Alzheimer's disease originally developed by the University of Leipzig in Germany. The test works by evaluating the cell surface marker CD69 on peripheral blood lymphocytes following a mitogenic stimulation. The underlying scientific basis for LymPro is that Alzheimer's patients have dysfunctional cellular machinery that inappropriately allows mature neurons in the brain to enter the mitotic process (cell division /cell cycle). When this happens the neurons start the cell division process, but cannot complete that process. As a result, a number of cytokines and other genes are upregulated, ultimately leading to cell death by apoptosis. This inappropriate cell division activation process is also present in the lymphocytes of Alzheimer's patients, as lymphocytes share a similar cellular division machinery with brain neurons. We measure the integrity of this cellular division machinery process by measuring CD69 upregulation in response to the mitogenic stimulation. If CD 69 is upregulated it means that the cellular division machinery process is correct and Alzheimer's is not present. If CD69 is not upregulated, it means there is a dysfunctional cellular division machinery process, and Alzheimer's is more likely. To date, data has been published in peer-reviewed publications on LymPro with 160 patients, demonstrating 92% co-positivity and 91% co-negativity with an overall 95% accuracy rating for LymPro.